Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.03 by 433.33 percent. This is a 62.96 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $17.699 million which beat the analyst consensus estimate of $17.200 million by 2.90 percent. This is a 15.02 percent increase over sales of $15.388 million the same period last year.